BRPI0809656B8 - atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica - Google Patents

atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica

Info

Publication number
BRPI0809656B8
BRPI0809656B8 BRPI0809656A BRPI0809656A BRPI0809656B8 BR PI0809656 B8 BRPI0809656 B8 BR PI0809656B8 BR PI0809656 A BRPI0809656 A BR PI0809656A BR PI0809656 A BRPI0809656 A BR PI0809656A BR PI0809656 B8 BRPI0809656 B8 BR PI0809656B8
Authority
BR
Brazil
Prior art keywords
atropisomer
compound
prophylactic
pharmaceutical composition
therapeutic agent
Prior art date
Application number
BRPI0809656A
Other languages
English (en)
Inventor
Tsuruoka Hiroyuki
Yoshida Juri
Aoki Kazumasa
Hayashi Noriyuki
Asoh Yusuke
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BRPI0809656A2 publication Critical patent/BRPI0809656A2/pt
Publication of BRPI0809656B1 publication Critical patent/BRPI0809656B1/pt
Publication of BRPI0809656B8 publication Critical patent/BRPI0809656B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica. é divulgado um agente a prevenção ou tratamento de doenças cardiovasculares. especificamente é divulgado um atropisômero de um composto representando pela seguinte fórmula geral (i) na fórmula, r1 representada um grupo de alquila c1-c3 ou um grupo de hidróxi-alquila c1-c3; e r2 é um átomo de hidrogênio ou um grupo de alcóxi c1-c3.
BRPI0809656A 2007-04-09 2008-04-08 atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica BRPI0809656B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007101938 2007-04-09
JP2007-101938 2007-04-09
PCT/JP2008/056907 WO2008126831A1 (ja) 2007-04-09 2008-04-08 ピロール誘導体のアトロプ異性体

Publications (3)

Publication Number Publication Date
BRPI0809656A2 BRPI0809656A2 (pt) 2014-10-07
BRPI0809656B1 BRPI0809656B1 (pt) 2019-07-09
BRPI0809656B8 true BRPI0809656B8 (pt) 2021-05-25

Family

ID=39863928

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809656A BRPI0809656B8 (pt) 2007-04-09 2008-04-08 atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica

Country Status (14)

Country Link
US (2) US8524918B2 (pt)
EP (1) EP2133330B1 (pt)
JP (1) JP5363312B2 (pt)
KR (2) KR20140048337A (pt)
CN (1) CN101679243B (pt)
BR (1) BRPI0809656B8 (pt)
CA (1) CA2683059C (pt)
DK (1) DK2133330T3 (pt)
ES (1) ES2448498T3 (pt)
IL (1) IL201261A0 (pt)
PL (1) PL2133330T3 (pt)
PT (1) PT2133330E (pt)
TW (1) TWI444185B (pt)
WO (1) WO2008126831A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102177137B (zh) * 2008-10-08 2015-03-18 埃克塞利希斯股份有限公司 1-苯基吡咯化合物
AU2009302371B2 (en) 2008-10-08 2015-02-12 Exelixis, Inc. Atropisomers of (hydroxyalkyl) pyrrole derivatives
WO2010098286A1 (ja) * 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
US8742102B2 (en) * 2009-03-26 2014-06-03 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
KR102234597B1 (ko) * 2013-04-10 2021-03-31 다이이찌 산쿄 가부시키가이샤 피롤 유도체의 결정 및 그 제조 방법
JP6422868B2 (ja) * 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
HUE037007T2 (hu) * 2013-08-27 2018-08-28 Daiichi Sankyo Co Ltd Eljárás pirrol származék elõállítására és annak intermediere
ME03316B (me) 2014-06-30 2019-10-20 Astrazeneca Ab Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora
CA2973944C (en) * 2015-01-26 2019-07-30 Daiichi Sankyo Company, Limited Solid composition of pyrrole carboxamide
CN105985295B (zh) * 2015-02-17 2018-11-20 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3434284A4 (en) * 2016-03-24 2019-11-13 Daiichi Sankyo Company, Limited MEDICINE FOR THE TREATMENT OF KIDNEY DISEASE
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
AU2020371836B2 (en) * 2019-10-25 2026-01-29 Sunshine Lake Pharma Co., Ltd. Pyrrole amide compound and use thereof
EP4118235B1 (en) 2020-03-11 2026-08-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
EP4317133B1 (en) * 2021-03-30 2026-04-15 Sunshine Lake Pharma Co., Ltd. Crystalline form of pyrrole amide compound, preparation method therefor and use thereof
US20240239746A1 (en) * 2021-04-26 2024-07-18 Sunshine Lake Pharma Co., Ltd. Preparation method for pyrrole amide compound
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
CN115784961B (zh) * 2021-09-10 2026-03-31 上海鼎雅药物化学科技有限公司 埃沙西林酮及其中间体的合成方法
WO2025011627A1 (zh) * 2023-07-12 2025-01-16 广东东阳光药业股份有限公司 制备吡咯甲酸化合物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JP2005532982A (ja) * 2001-09-24 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのピロール誘導体の製造及び使用
US6939968B2 (en) 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
DE10354060A1 (de) * 2003-11-19 2005-06-02 Merck Patent Gmbh Pyrrolderivate
PT1773768T (pt) * 2004-07-30 2018-11-30 Exelixis Inc Derivados de pirrol como agentes farmacêuticos
JP5123668B2 (ja) * 2005-01-10 2013-01-23 エグゼリクシス， インコーポレイテッド 医薬品としての複素環カルボキサミド化合物

Also Published As

Publication number Publication date
US20140024696A1 (en) 2014-01-23
US8524918B2 (en) 2013-09-03
BRPI0809656B1 (pt) 2019-07-09
TWI444185B (zh) 2014-07-11
TW200901968A (en) 2009-01-16
PL2133330T3 (pl) 2014-06-30
KR101477579B1 (ko) 2014-12-30
KR20140048337A (ko) 2014-04-23
HK1139942A1 (en) 2010-09-30
DK2133330T3 (da) 2014-03-31
CN101679243B (zh) 2012-09-26
JP5363312B2 (ja) 2013-12-11
ES2448498T3 (es) 2014-03-14
EP2133330B1 (en) 2014-01-01
KR20090127421A (ko) 2009-12-11
EP2133330A4 (en) 2010-08-11
EP2133330A1 (en) 2009-12-16
CA2683059A1 (en) 2008-10-23
BRPI0809656A2 (pt) 2014-10-07
CA2683059C (en) 2012-09-25
IL201261A0 (en) 2010-05-31
US8754118B2 (en) 2014-06-17
US20100093826A1 (en) 2010-04-15
WO2008126831A1 (ja) 2008-10-23
JPWO2008126831A1 (ja) 2010-07-22
CN101679243A (zh) 2010-03-24
PT2133330E (pt) 2014-03-31

Similar Documents

Publication Publication Date Title
MX2010009736A (es) Compuesto heterociclico.
BRPI1009637A2 (pt) composto, composição e uso de um composto
UA97257C2 (en) Indole derivatives
WO2008126831A1 (ja) ピロール誘導体のアトロプ異性体
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
UA105671C2 (uk) Фармацевтична композиція, яка містить похідне хіноліну
EA201100447A1 (ru) Органические соединения
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
WO2008036652A3 (en) Amidines as modulators of indoleamine 2,3-dioxygenase
TW200738651A (en) Cyclohexyl sulfonamide derivatives
BR112015025729A2 (pt) métodos para dividir e para produzir um composto, composto, composição farmacêutica, agente profilático ou terapêutico, e, uso de um cristal
GEP20135913B (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression
BR112012027387A2 (pt) composição para controle de doenças de plantas e uso da mesma
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
TW200716547A (en) Piperidin-4-yl-amide derivatives
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF